Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium‐glucose cotransporter‐2 (SGLT2) inhibitors compared with glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs): A pooled analysis of type 2 diabetes trials

To compare treatment effect sizes between a composite kidney outcome (CKO) and three‐point major adverse cardiovascular event (MACE‐3) outcomes with use of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), and to investigate the relationship between treatment effects on CKO and MACE‐3 in patients with type 2 diabetes (T2D).